Evidence map›Paper›PMID 34513597›Full record

ReviewWorld journal of clinical oncology2021

Liver transplantation in malignant disease.

Sven Arke Lang, Jan Bednarsch, Zoltan Czigany, Katharina Joechle, Andreas Kroh, Iakovos Amygdalos, Pavel Strnad, Tony Bruns, Daniel Heise, Florian Ulmer and 1 more

Open access · diamondAbstract readReview
In one paragraph

Review in World journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. [Frozen sections in hepatobiliary surgery].Chirurgie (Heidelberg, Germany) · 2025
    Review
  6. Review
  7. Liquid Biopsy by ctDNA in Liver Transplantation for Colorectal Cancer Liver Metastasis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sven Arke LangDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany. svlang@ukaachen.de.
Jan BednarschDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Zoltan CziganyDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Katharina JoechleDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Andreas KrohDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Iakovos AmygdalosDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Pavel StrnadDepartment of Internal Medicine III, University Hospital RWTH Aachen, Aachen 52074, Germany.
Tony BrunsDepartment of Internal Medicine III, University Hospital RWTH Aachen, Aachen 52074, Germany.
Daniel HeiseDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Florian UlmerDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
Ulf Peter NeumannDepartment of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen 52074, Germany.
RWTH Aachen University · DEUniversitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation for malignant disease has gained increasing attention as part of transplant oncology. Following the implementation of the Milan criteria, hepatocellular carcinoma (HCC) was the first generally accepted indication for transplantation in patients with cancer. Subsequently, more liberal criteria for HCC have been developed, and research on this topic is still ongoing. The evident success of liver transplantation for HCC has led to the attempt to extend its indication to other malignancies. Regarding perihilar cholangiocarcinoma, more and more evidence supports the use of liver transplantation, especially after neoadjuvant therapy. In addition, some data also show a benefit for selected patients with very early stage intrahepatic cholangiocarcinoma. Hepatic epithelioid hemangioendothelioma is a very rare but nonetheless established indication for liver transplantation in primary liver cancer. In contrast, patients with hepatic angiosarcoma are currently not considered to be optimal candidates. In secondary liver tumors, neuroendocrine cancer liver metastases are an accepted but comparability rare indication for liver transplantation. Recently, some evidence has been published supporting the use of liver transplantation even for colorectal liver metastases. This review summarizes the current evidence for liver transplantation for primary and secondary liver cancer.

Indexed as

Cholangiocellular carcinomaColorectal cancer liver metastasesHepatic epithelioid hemangioendotheliomaHepatocellular carcinomaLiver transplantationNeuroendocrine cancer liver metastasesUndifferentiated embryonal sarcoma of the liver

Identifiers

PMID34513597
PMCPMC8394155
OpenAlexW3195519387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.